Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senzime AB ( (SE:SEZI) ) just unveiled an announcement.
Senzime AB has secured inclusion of its TetraGraph neuromuscular monitoring system in purchasing agreements with Vizient, Premier, and HealthTrust Performance Group, the three leading US group purchasing organizations that collectively influence procurement for more than 5,000 hospitals. These listings significantly ease access to the US hospital market by integrating TetraGraph into key GPO catalogues used by roughly 95% of US hospitals.
The agreements do not immediately generate revenue but remove structural procurement barriers, provide pre-negotiated pricing, and are expected to shorten sales cycles and improve conversion of Senzime’s existing pipeline into orders. Management views the GPO coverage as a scalable platform for broader US adoption of TetraGraph over time, potentially enabling larger, system-wide deals with major hospital networks and strengthening the company’s competitive position in the US medical device market.
More about Senzime AB
Senzime AB is a Sweden-based medical device company focused on precision monitoring technologies that enhance perioperative patient safety. Founded in 1999 and headquartered in Uppsala, it develops and markets systems such as the TetraGraph, a neuromuscular monitoring solution used in thousands of operating rooms worldwide to optimize dosing of paralytic drugs and improve surgical outcomes. The company is listed on Nasdaq Stockholm with cross-trading on the US OTCQX Market and targets hospitals and healthcare providers adapting to new clinical guidelines and advanced monitoring standards.
Average Trading Volume: 245,052
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK760.1M
For an in-depth examination of SEZI stock, go to TipRanks’ Overview page.